CAT upholds pay-for-delay decision but trims penalties
The UK’s specialist competition tribunal has confirmed that GlaxoSmithKline and three generic drugmakers broke competition rules by entering into pay-for-delay agreements for the antidepressant drug paroxetine – but slashed the original fines by £27 million.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now